A platform company developing first-in-class biologics against severe neovascular and fibrotic disorders

About us

A spin-off from the laboratory of Dr. Gilles PAGES, University of Nice Cote d’Azur (Université de Nice Côte d’Azur) and the Institute for Research on Cancer and Aging (IRCAN)

A pipeline of antibodies against several validated targets in angiogenesis and lymphangiogenesis pathways

More than 20 years of internationally recognized cutting-edge research in cancer biology involving tumor angiogenesis and lymphangiogenesis

Therapeutic applications: metastatic cancers and fibrotic disorders

Therapeutic applications: metastatic cancers and fibrotic disorders

A team of seasoned scientists and biotech professionals
Incubated at SEMIA in Strasbourg

Founding team

A complementary team of 2 scientists and 2 business professionals

Zaki Sellam

CEO and President
of the Executive Board

Strategic positioning of the company, partnerships and negotiations

Anna Kamenskaya

Chief Operating Officer

Ensuring that R&D and operations of the company are carried out according to the strategic plan defined by the Board of Directors

Olivier Léger

Chief Scientific Officer

Leveraging wide experience and a strong track record in antibody engineering to develop KBs platform

Gilles Pagès

Senior Scientist

Bringing 20+ years of translational research in cancer biology to advance Kekkan’s products towards the clinic

The Translational Advisory Board

The TAB is a consultative scientific committee composed of scientists and clinicians who assist the founders with all scientific issues by providing advice and recommendations.

Daniel Olive, MD, PHD

Head of the Immunity and Cancer lab, CRCM

Professor of Immunology and Director of the Oncology Research Programs at Aix Marseille University.
Scientific Founder of ImCheck.

Delphine Borchiellini

Medical Oncology

Head of Department of Clinical Research and Innovation at Centre Antoine-Lacassagne, Nice

Bernard Escudier

Medical Oncology at Gustav Roussy Cancer Research Centre

Board member at Kidney Cancer Association (KCA)

President of the A.R.Tu.R association association A.R.Tu.R (association of researchers focused on kidney tumours).

Camillo Porta

Full Professor of Medical Oncology at the A. Moro University of Bari in Italy

Head of the Division of Medical Oncology at the AOU Consorziale Policlinico di Bari,President of the Italian Nephro-Oncology Group (GION)